Disposal Fees

No definition available.

Name:	rtrx_DisposalFees
Namespace Prefix:	rtrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Disposal of Assets, Present Value of Future Payments to be Received

+ References

No definition available.

+ Details

Name:	rtrx_DisposalofAssetsPresentValueofFuturePaymentstobeReceived
Namespace Prefix:	rtrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Disposal of Assets, Present Value of Future Payments to be Received, Discount Rate

+ References

No definition available.

+ Details

Name:	rtrx_DisposalofAssetsPresentValueofFuturePaymentstobeReceivedDiscountRate
Namespace Prefix:	rtrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents sales value of product rights.

+ References

No definition available.

+ Details

Name:	rtrx_SalesValueOfProductRights
Namespace Prefix:	rtrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2443-110228

+ Details

Name:	us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of gain (loss) on sale or disposal of intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7,9)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnDispositionOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	rtrx_AgreementAxis=rtrx_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rtrx_AsklepionPharmaceuticalsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rtrx_TuringPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rtrx_AgreementPaymentScheduleAxis=rtrx_AtTimeOfClosingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rtrx_AgreementPaymentScheduleAxis=rtrx_DueOnFirstAndSecondAnniversariesOfClosingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtrx_ManchesterPharmaceuticalsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rtrx_WaldunPharmaceuticalsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

BUSINESS COMBINATION AND DIVESTITURE OF ASSETS - Divestiture of Assets (Details) - USD ($) $ in Millions				12 Months Ended
	Jul. 02, 2015	Feb. 13, 2015	Jan. 09, 2015	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impact related to divestitures				$ 0.9
Asset Purchase Agreement \| Asklepion Pharmaceuticals LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 245.0
Discount rate of receivables	2.80%
Gain from the sale of the asset	$ 140.0
Disposal fees	4.9
Asset Purchase Agreement \| Turing Pharmaceuticals
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales value of product rights		$ 1.1	$ 1.0
At Time Of Closing \| Asset Purchase Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
PV of short term and long term receivables	46.2
At Time Of Closing \| Asset Purchase Agreement \| Asklepion Pharmaceuticals LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	150.0
Due On First And Second Anniversaries Of Closing \| Asset Purchase Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
PV of short term and long term receivables	44.9
Due On First And Second Anniversaries Of Closing \| Asset Purchase Agreement \| Asklepion Pharmaceuticals LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 47.5
Manchester Pharmaceuticals LLC \| Asset Purchase Agreement \| Turing Pharmaceuticals
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales value of product rights		0.3
Manchester Pharmaceuticals LLC \| Asset Purchase Agreement \| Waldun Pharmaceuticals, LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales value of product rights		$ 0.7